Difference between revisions of "Cladribine (Leustatin)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead")
m (Text replacement - "Category:Drug index" to "Category:Drugs")
Line 31: Line 31:
 
<references/>
 
<references/>
  
−
[[Category:Drug index]]
+
[[Category:Drugs]]
 
[[Category:Intravenous medications]]
 
[[Category:Intravenous medications]]
 
[[Category:Irritant chemotherapy]]
 
[[Category:Irritant chemotherapy]]

Revision as of 23:17, 13 June 2018

General information

Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.[1][2]
Route: IV
Extravasation: irritant or neutral, depending on reference

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 2/26/1993: Initial FDA approval

Also known as

  • Generic names: 2-chlorodeoxyadenosine, 2-CdA
  • Brand names: Leustatin, Litak, Movectro

References

  1. ↑ 1.0 1.1 Cladribine (Leustatin)) package insert
  2. ↑ Cladribine (Leustatin) package insert (locally hosted backup)
  3. ↑ Cladribine (Leustatin) patient drug information (Chemocare)
  4. ↑ Cladribine (Leustatin) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Cladribine_(Leustatin)&oldid=27818"